VERICI DX PLC LS-001
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more
VERICI DX PLC LS-001 (63V) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VERICI DX PLC LS-001 (63V) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VERICI DX PLC LS-001 - Net Assets Trend (None–None)
This chart illustrates how VERICI DX PLC LS-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VERICI DX PLC LS-001 (None–None)
The table below shows the annual net assets of VERICI DX PLC LS-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VERICI DX PLC LS-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VERICI DX PLC LS-001 Competitors by Market Cap
The table below lists competitors of VERICI DX PLC LS-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aurum Lake Mining Corporation
V:ARL
|
$703.78K |
|
Global Cannabis Applications Corp
PINK:FUAPF
|
$704.00K |
|
Curiox Biosystems Co. Ltd
KQ:445680
|
$704.28K |
|
Blue River Resources Ltd
PINK:BRVRF
|
$704.59K |
|
YHN Acquisition I Limited Right
NASDAQ:YHNAR
|
$702.29K |
|
VIS Containers Manufacturing Co. Ltd
AT:VIS
|
$702.03K |
|
VONTOBEL HLDG N
MU:VTLN
|
$701.86K |
|
DMC Mining Ltd
AU:DMM
|
$701.83K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VERICI DX PLC LS-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VERICI DX PLC LS-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VERICI DX PLC LS-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VERICI DX PLC LS-001's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VERICI DX PLC LS-001 (63V) | €- | N/A | N/A | $703.78K |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |